Life Biosciences shares glaucoma update for cellular reprogramming — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Life Biosciences shared updates on a glaucoma study involving its cellular reprogramming drug, per a STAT+ Readout report.
- The update was published as part of STAT+'s biotech newsletter, "The Readout," with the full article gated to STAT+ subscribers.
Why it matters: Glaucoma is a leading cause of irreversible blindness, and a cellular reprogramming approach — if clinically validated — would represent a mechanistic departure from existing pressure-lowering drugs, though no efficacy or timeline data is available in the disclosed update.
Ask SkimNews
